Leerink Partners on Hims and Hers (HIMS): FDA meeting to discuss peptide restrictions 'clear positive,' could fill growth hole
Tweet Send to a Friend
Leerink Partners analyst Michael Cherny reiterated a Market Perform rating and $25.00 price target on Hims and Hers (NYSE: HIMS)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
